Home
Science
Pipeline
Team
Media
Contact
Investors
אודות
Menu

Encouraging Interim Results of NeuroSense’s Clinical Study

Read about the promising preliminary results of our clinical trial in ALS patients.

09/09/2020/by avital

Share this entry

https://www.neurosense-tx.com/wp-content/uploads/2020/10/interim-results_resized.jpg 392 800 avital https://www.neurosense-tx.com/wp-content/uploads/2019/05/NEUROSENSE-THERAPEUTICS.png avital2020-09-09 11:32:142021-01-20 11:22:26Encouraging Interim Results of NeuroSense’s Clinical Study

Recent Posts

NeuroSense Completes Successful Phase IIa and Receives Patent Allowance
NeuroSense Granted European Orphan Drug Designation
NeuroSense’s Origins, Current Status and Plans Forward
NeuroSense Presents at ALS/MND Symposium
Continuation of Positive Trends in ALS Clinical Trial

Recent Posts

NeuroSense Completes Successful Phase IIa and Receives Patent Allowance
NeuroSense Granted European Orphan Drug Designation
NeuroSense’s Origins, Current Status and Plans Forward
NeuroSense Presents at ALS/MND Symposium
Continuation of Positive Trends in ALS Clinical Trial

HEAD OFFICE

Medinat Hayehudim 85, Herzeliya
Israel
tel: +972-9-9531142

Follow us

Clinical Studies Initiation and Orphan Drug Designation

Introducing the Women Behind NeuroSense

Skip to content

Accessibility Tools

Increase Text
Decrease Text
Grayscale
High Contrast
Negative Contrast
Light Background
Links Underline
Readable Font
Reset